Introduction Hepatitis B is a potentially deadly infection that can be acquired by exposure to infectious human blood or body fluids. While service members and others at occupational risk are routinely vaccinated to prevent hepatitis B, non-responders to this vaccine are at continued risk. Heplisav-B is a newer vaccine that may offer additional protection to those at risk. Materials and Methods Cases of hepatitis B vaccine non-responders who were given Heplisav-B after receiving six or more doses of standard hepatitis B vaccine were collected from existing health records within the military health system after Uniformed Services University of the Health Sciences Institutional Review Board review. Results Twelve of thirteen (92%) prior non-responders who were tested at least 1 month after completing the recombinant Heplisav-B vaccine series demonstrated seroprotection against hepatitis B. Conclusions Ideally, all service members and other at-risk workers should be protected from hepatitis B. This case series suggests that prior non-responders are likely to gain protection from hepatitis B with Heplisav-B vaccination. A prospective trial is warranted for further evaluation of this potential indication.

中文翻译：

---

先前乙型肝炎疫苗无反应者中的 Heplisav-B：病例系列

简介 乙型肝炎是一种潜在的致命感染，可通过接触具有传染性的人体血液或体液而获得。虽然服务人员和其他有职业风险的人定期接种疫苗以预防乙型肝炎，但对这种疫苗无反应的人仍处于风险之中。Heplisav-B 是一种较新的疫苗，可以为有风险的人提供额外的保护。材料和方法 在接受六剂或更多剂标准乙型肝炎疫苗后给予 Heplisav-B 的乙型肝炎疫苗无反应者的病例是在卫生科学机构审查委员会统一服务大学后从军事卫生系统内的现有健康记录中收集的审查。结果 在完成重组 Heplisav-B 疫苗系列至少 1 个月后接受检测的 13 名 (92%) 先前无反应者中，有 12 名 (92%) 显示出对乙型肝炎的血清保护作用。乙型肝炎。该病例系列表明，先前的无反应者可能会通过 Heplisav-B 疫苗接种获得对乙型肝炎的保护。有必要进行前瞻性试验以进一步评估这一潜在适应症。